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Background: Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important
role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation
sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral
infectivity, virion production, and antibody-mediated neutralization.
Results: Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated
neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost
infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity.
Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS
mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization
by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5
loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2)
made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355
(C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural
information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of
these mutations.
Conclusions: This report provides the first systematic experimental account of the biological role of the entire
PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV
infection cycle and for developing future anti-HIV strategies.
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The human immunodeficiency virus type 1 (HIV-1) Env
consists of a trimer of heterodimers of the gp120 surface
protein and the gp41 transmembrane protein [1-3].
HIV-1 gp120 is responsible for binding both the target
cell CD4 receptor and co-receptors (CCR5 or CXCR4)
[4,5], while gp41, together with gp120, mediates fusion
of the viral and host cell membranes for cell entry [6].
The gp120 monomer has five highly conserved (C1-C5)* Correspondence: wangyc@nifdc.org.cn
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reproduction in any medium, provided the orregions and five variable (V1-V5) regions. Crystal struc-
tures of gp120 reveal that these regions can be organized
into four structural domains: the inner and outer domains,
a 4-stranded bridging sheet, and the V1/V2 domain that
has been determined recently [7,8]. Upon CD4 receptor
binding, gp120 inner domain undergoes major structural
rearrangements to allow for bridging sheet formation;
whereas the majority of the outer domain appears to re-
main essentially unchanged [9]. Subsequent co-receptor
binding by areas located on the bridging sheet and V3
loop from the outer domain triggers additional gp120 con-
formational changes that promote eventual gp120 dissoci-
ation from gp41 and transition of gp41 into differenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Conservation of all 25 PNGS sites in FE among 36
HIV-1 strains
PNGS Region HIV-1
BC (% Cons.) B (% Cons.) AE (% Cons.)
N88 C1 100 100 100
N133 V1 50 8 8
N142 V1 75 0 0
N156 V1 100 100 100
N160 V1 92 75 92
N181 V2 92 0 0
N197 C2 100 92 100
N234 C2 92 58 92
N241 C2 100 100 100
N262 C2 100 100 100
N289 C2 100 83 100
N301 V3 100 100 92
N339 C3 100 83 8
N355 C3 92 100 0
N392 V4 100 75 67
N408 V4 25 42 0
N411 V4 50 75 0
N442 C4 67 0 0
N448 C4 100 100 100
N463 V5 33 42 8
N466 V5 50 42 42
N611 gp41 100 100 100
N616 gp41 100 92 100
N625 gp41 100 100 100
N637 gp41 100 100 92
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brane fusion [10,11].
This cascade of conformational changes leads to the ex-
posure of new epitopes on gp120 and gp41 for antibodies
to recognize. Classes of broadly neutralizing monoclonal
antibodies (MAbs) have been shown to neutralize HIV-1 by
binding different regions of Env, including the gp120 CD4
binding site (b12, VRC01, VRC03), the membrane proximal
region of the gp41 ectodomain (2F5, 4E10), and clusters of
glycans on the surfaces of gp120 (2G12, PG9, PG16) [12].
However, owing to the steric and kinetic constraints caused
by the continual structural rearrangements that occur, some
of these epitopes are only transiently exposed.
HIV-1 gp120 is heavily glycosylated by the infected host
with glycan moiety comprising about 50% of its total
mass [13]. These glycans influence Env conformations/
oligomerization, and affect viral entry, infectivity and anti-
body recognition [8,14-16]. Indeed, N-linked glycans are
essential for correct folding and processing of gp120 and
for the structural rearrangements of gp120 that occur dur-
ing CD4 and co-receptor binding that mediate membrane
fusion and cell entry of HIV-1 [17]. Additionally, the dense
glycans on the outer domain protect the virus from
antibody-mediated neutralization [18]. In gp41 of most
HIV-1 isolates, there are four consensus N-linked glycosy-
lation sites within a region flanked by two highly con-
served vicinal cysteines and a hydrophobic membrane
anchor domain [19]; however, little is known about the
function of the N-linked glycans on gp41. Despite the vast
literature on the N-linked glycosylation of gp120 and
gp41, the impact of individual N-linked glycans on HIV-1
infectivity and antibody-mediated neutralization has not
been systemically evaluated before.
The circulating recombinant forms (CRFs) of HIV-1,
CRF07_BC and CRF08_BC, are descendants of the par-
ental subtypes B from Thailand and C from India, and
are comprised of mostly subtype C in envelope. The
CRF07_BC recombinant strain has been one of the most
predominantly circulated HIV-1 strains in China. The
total potential N-linked glycosylation sites (PNGS) on
CRF07_BC Env range between 24–35 (mean=30), with a
mean of 25.8 in gp120 (range 20–30) and 4.2 in gp41
(range 2–6) [20]. The wild-type (wt) envelope, FE, was
cloned in our laboratory from a HIV-1 subtype 07_BC
infected patient obtained in Guangxi province in China.
25 PNGS exist on FE Env, 21 in gp120 and 4 in gp41.
In the present study, the effect of PNGS on viral in-
fectivity and antibody-mediated neutralization was
evaluated through systematic mutations of each PNGS
of Env and using pseudoviruses expressing the mutated
Env to assess the infectivity and sensitivity to the MAb-
mediated neutralization. In addition, we have utilized
structural data of gp120 and gp41 and molecular mod-
eling to evaluate the structural/functional relationshipof the PNGS based on what we have observed in our
systematic mutational study.
Results
Analysis of FE PNGS conservation among HIV-1 Isolates
We aligned the FE Env sequence with other HIV-1 isolates
(12 isolates of each clade): clade B (JRCSF, JR-FL, SF162,
YU-2, NL4-3, 89.6 and B01-06 [21]); clade BC (FE, sc19-15,
hb5-3, sc21-28, xj74-2, xj180-29, bj23-1, sc20-15, sc22-16,
yn99r-5, yn148r-9 and yn177-1 [20]); clade AE (GX91.2,
GX81.43, GX24.8, GX71.18, GX28.31, GX88.47, GX90.1,
BJX4.6, GX74.20, GX34.21, GX35.33 and BJ5.11 [22]) to
analyze the PNGS conservation. 20 out of the 25 PNGL
sites in FE strain are present in all or most strains (Table 1),
suggesting their high degree of conservation. The 3 PNGS
only present in subtype BC Env (underlined in Table 1) are
all located on V1/V2/C4. Generally speaking, the PNGS in
the constant regions (except N442) and gp41 are highly
conserved (Table 1).
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We compared the infectivity of FE with that of YU-2
(clade B), SF162.LS(clade B), 92BR025.9 (clade C) and
sc19-15 (clade 07_BC), and found that the infectivity of
FE strain was similar to those of the other HIV-1 strains
from the different clades (Figure 1a).
In order to determine whether Env mutants with PNGS
mutations could be incorporated into viral particles and
support viral infection, we generated pseudoviruses with
the PNGS mutants of Env and tested the capacity of these
pseudoviruses to infect TZM-bl cells (CD4+, CCR5+, and
CXCR4+). Except for N181, the location of all gp120
PNGS can be visualized on the FE gp120 monomer model
as shown in Figure 2a. All of the PNGS except for N392
are predicted to be on the surface of both the inner and
outer domains and the V1/V2 domain (Figure 2a). Two of
the gp41 mutations, N625 and N637, can be modeled
using available crystal structures of the gp41 core six hel-
ical bundle, which is proposed to be inserted into both the
cellular and viral membranes for membrane fusion
(Figure 2b) [23]. N625 is located on the linker region be-
tween the Heptad Repeat 1 (HR1) and HR2 alpha helices,
and N637, located on HR2, is predicted to be on the outer
surface of the six helical core (Figure 2b). Residues N611
and N616 are predicted to be on a loop in the linkerFE
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Figure 1 Infectivity assay of wt HIV strains and the PNGS mutants. a)
strains. b) Infectivity assay result of all FE PNGS mutants. c) Comparison of
2 isolates. Data are shown as relative luminescence units (RLU) in a logarith
(RLU of mutant) by Log10 (RLU of wt). The data represent the means of thr
deviations from the means. The cut off value of the infectivity assay is 4.0.region between HR1 and HR2 and are disordered in the
structures, and therefore, cannot be visualized in the
model.
Among these 25 mutants with N->Q mutations indivi-
dually, nine (N88Q, N156Q, N160Q, N181Q, N197Q,
N234Q, N241Q, N262Q, N289Q and N616Q) had signifi-
cant reduction in viral infectivity (Figure 1b) (p<0.05). Six
of these ten mutants (N156Q, N160Q, N181Q, N197Q,
N262Q and N289Q) were non-infectious. These nine
PNGS were mainly located in the C1, V1/V2, C2 regions
and one in gp41 (N616Q). Another group of seven mutants
(N133Q, N142Q, N301Q, N355Q, N392Q, N611Q and
N637Q) showed slight reduction of viral infectivity
(p<0.05). There are five mutants (N408Q (V4), N411Q
(V4), N442Q (C4), N448Q (C4) and N463Q (V5)) that had
a significant increase in viral infectivity (p<0.05), and three
mutants (N339Q, N466Q and N625Q) showed no differ-
ence in viral infectivity compared to the wt.
To determine the effects of substitution other than Gln
(Q) at PNGS, we mutated to Asp (D) (N->D) for the
PNGS at positions 88, 156, 160, 181, 197, 234, 241, 262,
289 and 616. Interestingly, compared with the completely
inactive N197Q and N289Q mutants, N197D and N289D
recovered some level of viral infectivity (Figure 1b, p>0.05).
Additionally, N88D showed a ~9-fold increase in infectivityN
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Figure 2 Structure models of FE Env, gp120 and gp41. a) Two views of the model of the FE gp120 monomer with grafted V1/V2 domain
(see Methods). The gp120 monomer consists of four domains: the inner domain (light blue), the outer domain (light pink), the bridging sheet
(orange), and the V1/V2 loop (dark blue). The 4 beta stranded bridging sheet forms upon CD4 binding near the CD4 binding loop (yellow). The
V3 loop (light green) extends from the outer domain. Mutated PNGS that increase or decrease viral neutralization by any of the MAbs are shown
as red sticks, and sites with negligible effects are shown as blue sticks. b) Two views of the model of the FE gp41 six helix bundle (see Methods).
The three alpha helices in the middle are shown in cyan, and the three helices on the outside are in green. Mutated PNGS N625 and N637 are
shown as red sticks. Aromatic residues W678, W680, and Y681 (yellow) from the MPRE region extend from the tip of each monomer and are
proposed to insert into the viral membrane (only one set of residues shown).
Wang et al. Retrovirology 2013, 10:14 Page 4 of 14
http://www.retrovirology.com/content/10/1/14compared to N88Q mutant and N234D showed a ~2-fold
increase. Others showed no difference in viral infectivity
compared with the N to Q mutants.
For these PNGS (N156, N160, N181, N197, N262 and
N289) with N->Q mutation that resulted in complete loss
of the infectivity, we also made the S/T to A mutation to
abrogate the glycosylation motif (NXS/T, X can be any
amino acid except proline). We found that the S/T->A
mutants showed no difference in viral infectivity com-
pared to the N->Q mutants, and that no activity was
detected in both N->Q and S/T->A mutants (data not
shown). These data suggest that the loss of infectivity of
N->Q mutation in these six mutants probably is due to
the loss of glycosylation.
The effect of PNGS mutations on viral infectivity in dif-
ferent HIV-1 isolates was also investigated by generatingPNGS mutations in other isolates that belongs to different
clades. We made mutations in HIV isolates Sc19-15 (clade
BC) and YU-2 (clade B) on those PNGS sites that signifi-
cantly influenced the FE infectivity (N88, N156, N160,
N197, N234, N241, N262, N289 and N616) by performing
both N->Q and N->K/T/S mutations. Additionally, we also
made N->K/T/S mutations on these sites in FE isolates.
The result showed that N->K/T/S/Q mutation of N156,
N160, N197, N262 and N289 resulted in complete loss of
the infectivity for FE, most of these mutations (except for
N156 and N289) also lost infectivity for the Sc19-15 isolate
(Figure 1c). Similarly, the mutational effect of N->Q muta-
tion of these PNGS sites was largely the same between FE
and Sc19-15. However, among the mutations in YU-2, only
one site, N262->Q/S showed complete loss of infectivity
(Figure 1c). For those mutations that still retained relatively
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Figure 3 Viral relative infectivity and virion incorporation of mutant gp120. Gp120 incorporation data are shown as the percentage of the
gp120/p24 ratio of the wt FE pseudovirus, with the wt gp120 incorporation set to 1.0. Relative infectivity was calculated by dividing the
Log10 (RLU of mutant) by Log10 (RLU of wt). The data represent the means of three independent experiments, and the error bars indicate the
standard deviations from the means. P values were calculated by using One-way analysis of variance (Tukey’s multiple comparison Test, SPSS
10.0). The difference of the mean infectivity and gp120 incorporation between wt and mutant is considered to be significant when a p value is
<0.05, which is indicated with an asterisk in the figure.
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lates, all PNGS mutations (except N234S) showed a slightly
reduced infectivity (but consistent) in FE than in the other
two isolates.
Effect of the PNGS Mutations on gp120 incorporation into
virions
To establish whether the loss of infectivity is caused by
solely the mutations of PNGS or by a defect in the mutant
gp120 incorporation into virions, we measured virus-
associated gp120 glycoprotein for each PNGS mutant of
FE Env. The mutant viruses were pelleted through a 25%
sucrose cushion, and then subjected to p24 and gp120
ELISAs. The ratios of gp120/p24 were calculated for each
virus to measure gp120 incorporation into virions, and are
shown in Figure 3 as the percentage of wt. In the control
experiments, cells were transfected with only plasmid
pSG3ΔEnv alone (expressing p24) or FE Env-expressing
plasmid alone (expressing gp120). As expected, after
ultra-centrifugation, no gp120 was present, but a similar
level of p24 was detected from the single pSG3ΔEnv trans-
fected pellet, and neither p24 nor gp120 were detected
from the FE Env-expressing plasmid transfected pellet.
Among all Env mutants, N88Q and N442Q in-
creased ~30% of gp120 incorporation compared to
wt (p<0.05) (Figure 3). N88D and N197Q showed
slightly enhanced gp120 incorporation (~12% of wt,p>0.05). Nine mutants (N197D, N241D, N339Q, N408Q,
N411Q, N448Q, N463Q, N466Q and N625Q) had slightly
reduced gp120 incorporation than wt (around 83% to 97%
of wt), mutants N289D and N637Q showed a 60%-66% of
wt level. Much lower levels of virus-associated gp120
glycoprotein (2% - 47% of wt) was observed for mutants
N133Q, N142Q, N156Q/D/S, N160Q/D, N181Q/D,
N234Q/D, N241Q, N262Q/D, N289Q, N301Q, N355Q,
N392Q, N611Q, N616Q/D (p<0.05).
While the gp120 incorporation is largely the same for
the N->Q mutants and N->D mutants on the same
PNGS, we found that N->D mutation at position N241
and N289 has much higher gp120 incorporation than
the N->Q mutations (Figure 3, p<0.05). The gp120 in-
corporation for N241Q was 12% of wt, but for N241D
was 85% of wt, even though both mutants essentially lost
all infectivity (Figure 3). However, for N289Q to N289D,
gp120 incorporation was 8% to 66% of wt, respectively,
which may correlate with the increase of infectivity from
undetectable for N289Q to 81% of wt for N289D
(Figure 3).
Effect of PNGS Mutations on Neutralization by MAbs
In the present study, 18 individual PNGS mutants were
tested in order to characterize their neutralization
phenotype by a panel of MAbs: b12, 2F5, 4E10, VRC01,
VRC03, PG9 and PG16. All other mutants that showed
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formation were excluded for the neutralization study.
As shown in Table 2 and Figure 4, different PNGS
mutations displayed varied sensitivity to different MAbs.
Among these mutants, the N197D showed a most pro-
found effect on the increase of susceptibility for a number
of MAbs. This N197D displayed a 37-fold increase in sus-
ceptibility to neutralization by VRC03, 17-fold increase to
MAb b12, 5-fold to both 2F5 and 4E10 (~5-fold), and 2-
fold increase to VRC01.
A few other mutants also showed a modest, but reprodu-
cible increase of susceptibility to some MAbs. For example,
N301Q showed an approximately 10-fold increase in sus-
ceptibility to neutralization by 2F5, a 5-fold increase to
4E10, and a 2-fold increase to b12, VRC01 and VRC03
(Table 2, Figure 4). N142Q showed about a 2-fold increase
in susceptibility to 2F5, 4E10 and b12. N289D showed a
10-fold increase in susceptibility PG16 and a 2-fold in-
crease to PG9. N355Q showed a ~5-fold increase in sus-
ceptibility to 2F5 and a ~8-fold increase in susceptibility to
4E10.
A few of the PNGS mutants also displayed reduced sus-
ceptibility to MAbs PG9 and PG16 (Table 2, Figure 4).
N197D had an 11-fold reduced susceptibility to
neutralization by PG9, and N142Q had a ~2-fold reduced
susceptibility to neutralization to PG9. About half of the
PNGS mutants also showed around 2-fold reduction in
susceptibility to PG16.
The FE and all three mutants on V/V2 (N133Q, N142Q
and N197D) were tested with four different monoclonal
antibodies targeting areas of the V3 domain: 447-52D,
2191, 2442 and 3869. All four strains were resistant to
mAbs 447-52D, 2191 and 2442 at highest IC50 (25 μg/
mL). However, even though wt FE also was resistant to
mAb 3869, all of the three V1/V2 mutants of FE became
more sensitive to mAb 3869, with the N142Q mutant
being 19 fold more sensitive (Table 2). This result suggests
that V1V2 may shield part of the V3 domain on an adja-
cent monomer within an assembled trimer.
Discussion
We made a complete set of systematically mutated N-
glycosylation Env mutants and conducted comprehen-
sive evaluation and analysis on their effects on viral
infectivity and neutralization by different classes of neu-
tralizing MAbs.
PNGS mutations and viral infectivity
We showed that all Env mutations on or near the V1/V2
domain had no infectivity or a reduced viral infectivity
(see Figure 3: N156Q/D/S, N160Q/D, 181Q/D and
N197Q inactive; N133Q, N142Q, N197D reduced activ-
ity). Previous studies suggest that the V1/V2 domain
undergoes CD4-induced conformational changes toexposure the co-receptor binding site [24]. A recent co-
crystal structure of V1/V2-PG9 shows that the V1/V2
orientation varies dramatically in the context of the
monomeric gp120 [8]. To gain structural insights of the
glycan mutants located on V1/V2, we grafted a model of
the FE V1/V2 domain onto the FE gp120 core model
(Figure 2a). We also analyzed how this model may oligo-
merize in a gp120 trimer based on models from cryo-ET
[25]. Even though modeling the V1/V2 domain based
on the unliganded trimer model had steric clashes
(Figure 5a), no clashes are present when modeling is based
on the gp120 trimer model in the CD4-bound form
(Figure 5b). Our model is consistent with cryo-ET studies
suggesting that the V1/V2 domain undergoes reposition-
ing in the “closed” and “open” conformations of the Env
trimer [25,26]. This model also agrees with studies that
propose that the V1/V2 domain from one monomer may
interact with an adjacent monomer in the trimer to shield
the neighboring V3 loop from antibody binding [27]. Our
neutralization test of infectivity of three V1/V2 mutants of
FE using anti-V3 mAb 3869 showed a marked increase of
sensitivity, providing evidence supporting such a shielding
hypothesis.
The long V3 loop extends from the gp120 outer do-
main that remains fairly stable during receptor/co-recep-
tor binding; thus, it is not thought to undergo large
conformational changes as V1/V2 domain [29]. This gly-
cosylated loop determines the specificity of the co-
receptor and could act as a “molecular hook” that binds
the co-receptor and perhaps other gp120 molecules in
the trimer (Figure 2a and 5a, lower panel) [29,30]. Thus,
N301 at the stem of the V3-loop may play a role in sta-
bilizing the V3 and modulating co-receptor binding
(Figure 2a). Therefore, the drastic decrease of viral infect-
ivity seen by mutant N301Q may be due to a decrease in
co-receptor binding. Interestingly, N442Q showed almost
a 2-fold increase in viral infectivity (Figure 3). This residue
is located on a loop neighboring the V3-loop and N301
(Figure 2a). Thus, removal of the glycan may indirectly in-
crease viral activity by causing a shift in the V3 loop, lead-
ing to an increase in co-receptor binding.
PNGS mutants N262Q/D and N289Q showed a
complete lack of viral infectivity (Figure 3). Interest-
ingly, N289D displayed viral infectivity (Figure 3), and
showed much higher gp120 incorporation than N289Q.
We could not offer a good explanation for this observa-
tion. These residues are located right in the junction
between the inner and outer domains of gp120 that
undergoes major conformational changes (Figure 2a)
[7,31], thus, these mutations could affect the conform-
ational changes that are necessary for cell entry.
Previous studies also indicate the importance of glyco-
sylation at N262 for gp120/gp41 expression in the viral
particle [32]. Thus, glycans in this area are likely
Table 2 Neutralization of Env glycosylation mutants by MAbs
Env Region
MAbs/IC50 (μg/mL)(%)
Percentage of neutralization sensitivity relative to WT
2F5 4E10 b12 VRC03 VRC01 PG9 PG16 3869
FE(WT) - 2.224 (100) 2.986 (100) 0.088 (100) 2.601 (100) 5.500 (100) 1.415 (100) 7.600 (100) >25 (100)
N88D C1 1.097 (203) 1.840 (162) 0.201 (44) 3.427 (76) 4.936 (111) 0.988 (143) 12.847 (59) ND
N133Q V1/V2 1.571 (142) 1.776 (168) 0.123 (72) 2.962 (88) 5.178 (106) 2.479 (57) 16.233 (47) 5.035 (>496)
N142Q V1/V2 1.117 (199) 0.999 (299) 0.035 (251) 2.944 (88) 5.100 (108) 3.041 (47) 16.350 (46) 1.315 (>1901)
N197D V1/V2 0.396 (562) 0.477 (626) 0.005 (1760) 0.070 (3716) 2.355 (234) 16.123 (9) >25 (<30) 5.540 (>451)
N289D C2 1.250 (178) 1.544 (193) 0.150 (59) 2.539 (102) 3.800 (145) 0.519 (273) 0.731 (1040) ND
N301Q V3 0.210 (1059) 0.585 (510) 0.040 (220) 1.235 (211) 2.330 (236) 0.875 (162) 14.884 (51) ND
N339Q C3 1.127 (197) 1.579 (189) 0.083 (106) 1.799 (145) 4.899 (112) 1.664 (85) 14.644 (52) ND
N355Q C3 0.426 (522) 0.353 (846) 0.060 (147) 1.980 (131) 5.456 (101) 0.800 (177) 15.250 (50) ND
N392Q V4 1.265 (176) 2.327 (128) 0.051 (173) 4.908 (53) 5.678 (97) 1.091 (130) 14.064 (54) ND
N408Q V4 1.505 (148) 2.010 (149) 0.063 (140) 2.938 (89) 5.777 (95) 1.775 (80) 16.512 (46) ND
N411Q V4 1.072 (207) 1.302 (229) 0.082 (107) 3.511 (74) 5.230 (105) 0.900 (157) 14.783 (51) ND
N442Q C4 0.781 (285) 0.934 (320) 0.045 (196) 0.791 (329) 4.120 (133) 1.650 (86) 16.111 (47) ND
N448Q C4 0.635 (350) 0.694 (430) 0.057 (154) 2.917 (89) 4.987 (110) 0.878 (161) 13.386 (57) ND
N463Q V5 0.763 (291) 0.895 (334) 0.056 (157) 2.170 (120) 3.450 (159) 2.544 (56) 16.333 (47) ND
N466Q V5 1.339 (166) 1.397 (214) 0.087 (101) 2.139 (122) 3.204 (172) 3.070 (46) 16.378 (46) ND
N611Q gp41 1.836 (121) 0.704 (424) 0.116 (76) 3.103 (84) 5.431 (101) 1.797 (79) 15.830 (48) ND
N625Q gp41 0.400 (556) 0.577 (518) 0.041 (215) 3.329 (78) 5.398 (102) 1.069 (132) 16.450 (46) ND
N637Q gp41 1.429 (156) 1.168 (256) 0.102 (86) 2.812 (92) 5.178 (106) 1.342 (105) 13.411 (57) ND
Percentage of neutralization sensitivity relative to WT (%) = IC50 WT / IC50 mutant.
ND: not detected.
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rearrangements.
Although there is no available co-crystal structure of
gp120 with gp41, studies indicate that residues on the
gp120 inner domain β-sandwich are important for gp41
interaction and gp41 transitions [33]. Residues N88, N234,
and N241 in this region have previously been identified in
the non-covalent gp120-gp41 interactions (Figure 2a and
5a, lower panel “gp41 interactive region”) [34-39]. There-
fore, reduced viral infectivity of these mutations may be a
result of inefficient viral entry due to lack of proper inter-
actions of gp120 with gp41.
CD4 and co-receptor binding initiate structural changes
in gp120 and gp41 that mediate fusion of the viral and cel-
lular membranes. Three gp41 states have been proposed:
the prefusion, the prehairpin intermediate, and the post-
fusion conformations [10]. We generated a FE gp41 model
based on the gp41 late fusion intermediate state, which
is thought to stabilize membrane fusion pore opening
(Figure 2b) [23]. The model is a 6-helix bundle core
(Figure 2b). Our studies show that mutation of gp41 resi-
dues 611, 616, and 637 reduced viral infectivity, whereas
N625Q showed no change in viral infectivity (Figure 3).
N625 and N637 can both be visualized on our FE gp41
model (Figure 2b) [23]. However, N611 and N616,although present in the crystalized gp41 constructs, are
not visible due to their location on the flexible loop. Previ-
ous studies showed that only one of the glycans at position
611 and 616 is actually glycosylated, likely only N611
[40,41]. In our FE gp41 model, N637 is located on the
outer surface of the helix bundle (Figure 2b), which is con-
sistent with the previous report that N637 is glycosylated
[40,41]. Nonetheless, mutation at N637 only had a rela-
tively small effect on the infectivity (Figure 3). N611 and
N616, located on the linker region, may play a role in other
gp41 conformations that could affect gp120 incorporation
into virion (Figure 3), and mutations of these residues
resulted in more loss of infectivity. N625 points away from
the helix bundle (Figure 2b), which would explain why its
mutation does not affect viral infectivity.
A previous study, which focused on the effect of 28
PNGS in viral infectivity of a clade B virus, reported that
only three sites (N262, N332 and N386) are detrimental for
infectivity for isolate YU-2 and that only N262 is also detri-
mental in another clade B isolate JRFL [42]. In our study,
we also showed that the same N262 is detrimental for in-
fectivity for clade BC (isolates FE and Sc19-15) as well as
for clade B (isolates YU-2 and NL4-3 [32]). However, we
found that N332 and N386 were dispensable for infectivity
for the clade BC virus. In addition, we found that mutation
Figure 4 Neutralization susceptibility of WT FE and PNGS mutants by several known neutralizing MAbs. All data points represent the
means and the error bars indicate the standard deviations from the means that were obtained from three independent experiments.
Neutralization assays of the pseudovirions produced from WT and mutants were described in Materials and Methods.
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Figure 5 Modeled FE gp120 trimers. a) Model of unliganded FE gp120 trimer containing the truncated V1/V2 stem loop in a “closed”
conformation (Upper and lower panels). Top and front views showing the closed conformation of an HIV-1 FE gp120 trimer. We were unable to
model the recently solved complete V1/V2 domain onto the unliganded trimer model due to steric clashes; however, a portion of the truncated
V1/V2 domain, the V1/V2 stem loop (dark blue), can be seen in a “closed” conformation near the center of the trimer. More structural information
is needed regarding the unliganded full-length gp120 trimer to determine precisely where the complete V1/V2 domain is positioned in this
conformation; however, owing to its flexibility, the V1/V2 domain will likely also be positioned near the center of the trimer. This is also consistent
with cryo-electron tomography studies [26,28]. b) Model of CD4 bound FE gp120 trimer containing the complete V1/V2 domain in an “open”
conformation. Top and front views showing the open conformation of the trimer upon binding the CD4 receptor. We were able to graft the
complete V1/V2 domain (dark blue) onto the gp120 core. Upon CD4 binding, the V1/V2 domain rotates outwardly in an “open” orientation,
consistent with cryo-electron tomography studies [26,28].
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N197Q, N262Q and N289Q) in the FE isolate resulted in
non-infectious virus and mutation of most of these sites
yielded similar results in another clade BC isolate Sc19-15.
Our data would imply that there are dramatic differences
in the glycan dependence of clade B and clade BC isolates.
Clade B appears to be insensitive to most glycan removals,
with only 1–3 sites being important for infectivity, while
the infectivity of clade BC isolates are much more sensitive
to the mutation of many more glycan sites.PNGS mutations and MAb neutralization
For those glycosylation mutants that showed viral infectiv-
ity, we examined their sensitivity to seven broadly neutraliz-
ing MAbs [43,44]. The neutralization ability of CD4bs
MAbs showed a marked increase for the N197D mutant,
with b12 displaying a >17-fold increase over wt FE and
VRC03 also displaying a >37-fold increase (Table 2). Stud-
ies show that the N197 mutation significantly increases b12
susceptibility of HIV strains JR-CSF, 89.6, and CRF01_AE
[45-47]. As previously discussed, N197 is located near the
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shields the bridging-sheet, which may affect CD4 receptor
and co-receptor binding. Therefore, removal of the N197
glycan could result in the removal of the glycan shield,
and/or a shift of V1/V2, which may allow the CD4bs
MAbs to better access their epitopes, thus increasing sen-
sitivity to neutralization. Interestingly, the structures of
the gp120 core (missing V1/V2) in complex with the three
CD4bs-MAbs show that they are positioned differently,
with b12 being the closest, VRC03 next, and VRC01 the
farthest to V1/V2 [48-50]. This positioning relative to the
V1/V2 domain may explain why b12 and VRC03 show a
higher increase in neutralization by the N197 mutant
compared with VRC01. It is also possible that the V1/V2
conformational changes could affect adjacent binding sites
in the trimer [47]. Our data also indicate that the V1V2 re-
gion of one monomer may shield part of the V3 binding
site on an adjacent monomer within a trimer.
Unlike our results seen from the CD4bs MAbs, almost
all of the PNGS mutants tested displayed a 2–10 fold in-
crease in susceptibility to neutralization by the anti-gp41
MAbs, 2F5 and 4E10 (Table 2). Both 2F5 and 4E10 act to
inhibit the fusion process by binding the highly conserved
Membrane Proximal External Region (MPER) region of
gp41 [51,52]. The MPER region of gp41 may only be
exposed during the transient prehairpin intermediate state
in which gp41 is in an extended conformation [10]. Hence,
2F5/4E10 would only have a short time period to bind their
epitopes, which may explain why the 2F5- and 4E10-like
antibodies are rarely found in HIV-1-infected plasma [10].
Any conformation changes in gp120/gp41 that would en-
hance receptor binding may promote increased
neutralization by 2F5/4E10. In our study, 2F5 and 4E10
showed an increase in neutralization to the majority of our
mutants, indicating that the presence of glycans may some-
how interfere with anti-gp41 MAb binding (Table 2). Simi-
lar to our results, deglycosylation of Env enhanced binding
of 2F5 and 4E10 MAbs [53]. These results may indicate
that removal of glycans may allow more flexibility for
gp120/gp41 rearrangement that leads to the exposure of
the MPER region of gp41.
Quaternary-specific MAbs PG9 and PG16 recognize
gp120 epitopes composed of glycans on the V1/V2 domain
[54]. A recent crystal structure shows that two glycans
(N156/N160) and a V1/V2 β-strand form the PG9 recogni-
tion site [8]. One conspicuous observation in this study is
that PG9 and PG16 are the only MAbs that displayed
decreased neutralization activity for some PNGS mutants,
with PG16 having a more dramatic decrease (higher IC50)
than PG9 (Table 2). Furthermore, PG9/PG16 MAbs show
major decreases in neutralization toward the N197D mu-
tant. Because N197 is near the V1/V2 domain, this glycan
may also affect the PG9/P16 epitope. Alternatively, perhaps
N197D affects the positioning of the V1/V2 domain withinthe Env trimer. Based on our model of the FE trimer in un-
bound and CD4-bound form, the V1/V2 domain under-
goes major conformational changes (Figure 2b and 5a). In
the CD4-unbound “closed” state, the gp120 monomers and
their V1/V2 domains are packed tightly together at the
apex (Figure 5a), whereas, after CD4 binding, the V1/V2
rotate outward in the “open” state (Figure 5b) [25]. As
PG16 recognizes the gp120 epitope significantly better in
trimer form, perhaps the N197D mutant alters the con-
formation of the V1/V2 domain in the trimer resulting in a
shift of the epitope to reduce PG16 binding.
Similar to PG9/PG16, MAbs PGT127 and PGT128 are
also glycan dependent for neutralizing activities. PGT128
recognizes two conserved glycans at N301/N332 as well
as a short β-strand segment of the gp120 V3 loop [55].
Substitutions at N332/N301 resulted in the loss of neu-
tralizing activity against most isolates. Previous analysis
revealed that N295, N332, N339, N386, N392 and N448
are likely involved in the 2G12 epitope [56].
In the present study, our results indicated that wt and all
PNGS mutants of FE were resistant to 2G12 at the highest
concentration tested (25 μg/mL MAbs) (data not shown).
FE lost the N295, N332 and N386 PNGS that were sug-
gested to be involved in 2G12 binding. We re-introduced
these three PNGS into FE Env together, which remained re-
sistant to 2G12 in our experiments (data not shown). 2G12
broadly neutralizes clade B isolates and is less effective
against other clades, particularly clade C viruses, which
have a somewhat different oligomannose glycan arrange-
ment than clade B viruses. The continued insensitivity to
2G12 for the re-introduced mutant suggests the role of
other residues in forming 2G12 epitope. A previous study
showed that 447-52D can neutralize most subtype B viruses
which contain the peptide GPGR at the tip of the V3 tip,
but infrequently neutralized other clades [57]. The wt FE
and all mutants are all GPGQ at the tip of the V3 loop, this
may explain why the viruses in our study are resistant to
mAb 447-52D.
Conclusions
In summary, through systematic mutations of all the PNGS
of the Env gp120 and gp41 proteins, we have charted for
the first time the relative significance of each of the PNGS
of the FE Env for their biological functions in virion forma-
tion, viral infectivity, and MAb sensitivity. Using molecular
modeling based on the available rich structural information
in the literature, we provide the structural and functional
correlation for the biological effects of most of the PNGS
observed in our study, which should be valuable for our
understanding of the roles of the respective glycans in HIV
infection and host immunity. Furthermore, the results of
the increased or decreased sensitivity to neutralizing anti-
bodies after PNGS mutations will be valuable information
for future design of anti-HIV/AIDS strategy.
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Cells and plasmid
TZM-bl (JC53-bl) cells, Env-deficient HIV-1 backbone
(pSG3ΔEnv) were obtained from the US National Institutes
of Health (NIH) AIDS Research and Reference Reagent
Program (ARRRP), as contributed by John C. Kappes,
Xiaoyun Wu, and Tranzyme (Birmingham, AL). The
293FT cells were obtained from Invitrogen (Carlsbad, CA).
MAbs
MAbs 2F5, 4E10, 2G12 and b12 were obtained from the
International AIDS Vaccine Initiative (IAVI, New York,
NY); MAbs 2F5 and 4E10 were contributed by Hermann
Katinger (Institute of Applied Microbiology, Vienna, Aus-
tria) and b12 was contributed by Dennis Burton and Carlos
Barbas (The Scripps Research Institute, La Jolla, CA);
MAbs VRC01, VRC03, PG9, PG16 and anti-V3 MAbs
(447-52D, 2191, 2442 and 3869) were obtained from the
ARRRP (NIH).
Elimination of PNGS by mutagenesis
The motif for an N-linked glycosylation site is Asn-X-Thr/
Ser, where X can be any amino acid except proline [58].
Elimination of PNGS was performed using site-directed mu-
tagenesis, by changing an asparagine (N) to a glutamine (Q)
or aspartate (D). The wt Env gene was inserted into pcDNA
3.1D/V5-His-TOPO (Invitrogen) as a template for mutagen-
esis. Mutagenesis was performed using approximately 50 ng
plasmid DNA template and 1 μL of 1 μM primer F (for-
ward), R (reverse) were added into the PCR mixture which
contain 10 μL 5X PrimeSTARW buffer (Mg2+ plus) (TaKaRa,
Dalian, China), 4 μL dNTP mixture (2.5 mM) and 0.5 μL
PrimeSTARWHS DNA polymerase (2.5 U/μL) (TaKaRa),
then add ddH2O to a total volume of 50 μL. Standard PCR
and cloning procedure were used to obtain the mutant
clones. All 25 PNGS of wt FE Env were mutated individually
to have N to Q/D mutations at the positions shown in
Table 1 (positions in HXB2 numbering throughout the
manuscript). The entire Env gene of each mutant was
sequenced to confirm mutation. The conservation of the 25
PNGS of FE Env with other HIV-1 is shown in Table 1. The
primers used for mutagenesis are listed in Additional file 1:
Table S1.
Pseudovirus preparation, infectivity, titration and
neutralization assays
Pseudoviruses were produced by co-transfection of 293FT
cells (>90% confluency in a 25 cm2 rectangular canted neck
cell culture flask, Corning, USA) with 5.3 μg pSG3ΔEnv
plasmid and 2.7 μg Env-expressing plasmids using the
Lipofectamine 2000 reagent (Invitrogen). Supernatants
were harvested 48 hr after transfection, filtered (0.45-μm
pore size), and stored at −80°C. The concentration of HIV-
1 Gag p24 antigen in viral supernatants was measured byenzyme-linked immunosorbent assay (ELISA) (Vironostika
HIV-1 antigen micro-ELISA system; bioMérieux, Boxtel,
The Netherlands).
A fixed amount of pseudovirus (equivalent to 1.0 ng p24
antigen) was added to TZM-bl cells at 70−80% confluency
in a 96-well plate in the presence of 15 μg/mL DEAE-dex-
tran, in a total volume of 200 μL. 48 hr after infection, the
luciferase activity in infected cells was measured using the
Bright-Glo™ luciferase assay system (Promega, Madison,
WI). Relative infectivity was calculated by dividing the
Log10 (RLU of mutant) by Log10 (RLU of wt).
The 50% tissue culture infectious dose (TCID50) of a
single infectious pseudovirus batch was determined in
TZM-bl cells, as described previously [59].
Neutralization was measured as a reduction in lucifer-
ase expression after a single-round infection of TZM-bl
cells with pseudoviruses according to previously pub-
lished method [21].
Gp120 incorporation into virions
293FT cells were co-transfected with plasmid pSG3ΔEnv and
Env-expressing plasmids. Viral supernatants were harvested
and filtered (0.45-μm pore size) 48 hr post transfection, then
were pelleted through a 25% sucrose cushion by ultracentri-
fugation at 100,000 × g for 2.5 hr. The layers of supernatant
and sucrose were removed, and the resulting viral pellets
were resuspended in 250 μl PBS. The viral pellets were sub-
jected to p24 ELISA, and gp120 ELISA (Immune Technol-
ogy Corp, USA) [60-62] to determine the amount of p24
and gp120. Incorporation was determined by calculating the
ratio of gp120 to p24. The supernatant of transfected cells
by single plasmid pSG3ΔEnv or FE Env-expressing plasmid
were set as control, which were performed as the viral
supernatant above.
Structural modeling
The core FE gp120 model was created using the previously
solved structure of truncated gp120 from a clade B HIV-1
isolate, JR-FL (PDB: 2B4C), as a template. Based on an
alignment using Multalin, deletions were made to the FE
gp120 sequence to correspond with the truncations made
in the JR-FL sequence of the crystallized construct. The
comparative homology modeling program SWISS-
MODEL was used to generate the FE gp120 model. The
FE V1/V2 domain model was generated similarly using
the recently solved structure of the V1/V2 domain from a
clade C isolate, CAP4 (PDB: 3U4E) as a template. The FE
gp120 model including the V1/V2 domain was created in
PyMOL by manually grafting the V1/V2 loop model onto
the FE gp120 monomer model based on sequence and
structural alignments of the limited overlapping sequences
between the two molecules. The model of the FE gp41
was generated using the structure of the gp41 six-helical
core bundle of the HXB2 group M subtype B isolate
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we first generated an FE monomer model using the unli-
ganded SIV gp120 structure as a template (PDB: 2BF1).
The model was generated with Multalin and SWISS
MODEL as described above. Our FE unliganded mono-
mer model was then superimposed onto each of the
monomers in the “closed” trimer model that was gener-
ated from cryo-ET (“closed” state PDB: 3DNN). The FE
gp120 trimer model in the “open” CD4 bound state was
generated by superimposing our FE gp120 monomer with
V1/V2 domain model onto each of the monomers in the
CD4 bound trimer model generated from cryo-ET (“open”
CD4 bound state PDB: 3DNO).
Statistical analysis
Error bars indicate the standard deviation of the means
calculated by Prism software 5.0. One-way analysis of
variance with Tukey’s multiple comparison was used to
test whether the mean infectivity and gp120 incorpor-
ation is significantly different between wild type and
mutants by SPSS 10.0. A p value <0.05 was considered
significant and is depicted by an asterisk in Figure 3.Additional file
Additional file 1: Table S1. List of primers used for site-directed
mutagenesis to eliminate potential N-linked glycosylation sites in the FE
envelope.Abbreviations
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external region.
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